PD-1/PD-L1抗体治疗胃肠道癌症的研究进展

Research progress of PD-1/PD-L1 antibody treatment for gastrointestinal cancer

胃肠道癌是消化系统常见的恶性肿瘤,晚期胃肠道癌治疗方法局限,预后差。近几年随着肿瘤免疫研究的突破性进展,免疫检查点抑制剂如PD-1/PD-L1抗体已成为一种新的肿瘤临床治疗药物。在胃肠道肿瘤方面,派姆单抗已被美国FDA批准用于治疗晚期或转移性胃癌,日本也已将纳武单抗批准用于晚期及进展期胃癌。最近的一系列临床试验也证实了应用派姆单抗与纳武单抗对于高微卫星不稳定性(MSI-H)或错配修复缺陷(dMMR)的晚期结肠癌患者有效。本文对近年来应用PD-1/PD-L1抗体纳武单抗和派姆单抗单药与联合治疗胃肠癌的临床研究进展做一综述。

Gastrointestinal cancer is a common malignant tumor of the digestive system.Recently,the application of immunocheckpoint inhibitor such as PD-1/PD-L1 antibody has become a new therapeutic drug with the breakthrough research on the tumor immunology.In terms of gastrointestinal tumors,pymumumab has been approved for advanced or metastatic gastric cancer by the U.S.FDA and for advanced and advanced gastric cancer in Japan.Several clinical trials in recent years have also demonstrated the efficacy of pyimumab and opuumab in advanced colon cancer patients with high microsatellite instability(MSI-H)or mismatched repair defects(dMMR).In this paper,we aim to reviewe the recent progress in clinical studies of PD-1/PD-L1 antibodies nivolumab and pembrolizumab for treating gastrointestinal cancer.